Alli is an inhibitor of gastrointestinal lipase.
One capsule of Alli contains such an active ingredient as Orlistat - 120 mg, and additional components such as Carboxymethyl starch sodium, microcrystalline cellulose, povidone, talc, sodium lauryl sulfate.
Alli is a specific inhibitor of gastrointestinal lipases. The mechanism of its active substance is due to the formation in the lumen of the small intestine and stomach a covalent bond with the active serine center of pancreatic and gastric lipases. As a result, the enzyme that has lost activity is not able to break down the fats that come from food in the form of triglycerides.
Under the activeness of the drug, which is 24–48 hours after its use, the concentration of fat in the stool mass increases. By reducing the fat, Alli provides control of body weight. For the effective action of the drug, it is not required its absorption into the systemic circulation.
Indications for the treatment of obesity, including the provision of reducing and maintaining body weight, in combination with a low-calorie diet.
• Malabsorption syndrome;
• age up to 18 years;
• pregnancy and breastfeeding;
• simultaneous use with cyclosporine;
• hypersensitivity to any of the components of the drug.
• Take the drug with caution if you have nephrolithiasis (the presence of calcium oxalate stones).
Side effects of Alli are:
• Extremely rare - increased activity of transaminases and alkaline phosphatase, hepatitis;
• Immune system: rash, itching, bronchospasm, angioedema, anaphylaxis;
• Respiratory system, chest and mediastinal organs: very often - infections of the upper respiratory tract.